While most biotech startups chase the hype of AI drug discovery, Codexis is quietly dominating a far more tangible frontier: engineering enzymes for RNA manufacturing. With $162M in funding and a revenue of $101.3M, this isn't a lab experiment—it's a commercial engine.

"They aren't just building enzymes; they're building the manufacturing infrastructure for the next generation of RNA therapeutics."

The tech stack reveals a modern, agile approach. Using Vite and Tailwind CSS suggests a lean, frontend-optimized web presence, while Cloudflare and PHP indicate a robust, scalable backend. Interestingly, the lack of heavy React frameworks might imply a focus on speed and stability over flashy interactivity—exactly what you want from a company handling complex biological data.

• Strategic Pivot: Moving from broad enzyme discovery to focused RNA manufacturing tools.
• Leadership Stability: Led by CEO John Nicols, with a core team retaining significant tenure.
• Niche Dominance: 'Codexis food enzymes' remains a top keyword, showing legacy strength in industrial biotech.